Regeneron Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Regeneron Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Regeneron Pharmaceuticals Inc Strategy Report
- Understand Regeneron Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreRegeneron Pharmaceuticals Inc (Regeneron) discovers, develops, manufactures, and markets medicines for the treatment of serious medical conditions. Its products are focused on helping patients suffering from cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, hematologic conditions, pain, and rare diseases. Regeneron develops products using its Trap and VelociSuite technology platforms, which include VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, and other related technologies. The company operates manufacturing facilities in Rensselaer, New York, and Limerick. It also collaborates with strategic partners to develop, manufacture, and commercialize its products. It sells its products to specialty pharmacies and distributors. The company operates in the US, the Netherlands, Bermuda, Ireland, Spain, India, Japan and the UK. Regeneron is headquartered in Tarrytown, New York, the US.
Headquarters
United States of America
Address
777 Old Saw Mill River Road, Tarrytown, New York, 10591-6717
Website
www.regeneron.com
Telephone
1 914 8477000
No of Employees
13,450
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
REGN (NASD)
Revenue (2022)
$13.1B
7.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-8.9%
(2022 vs 2021)
Market Cap*
$99.3B
Net Profit Margin (2022)
XYZ
-15.4%
(2022 vs 2021)
* As of and is in US$
Regeneron Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Eylea (Aflibercept) Injection | Arcalyst |
| Arcalyst (Rilonacept) | Evkeeza |
| Praluent (alirocumab) Injection | Eylea |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Acquisitions/Mergers/Takeovers | In April, the company acquired the oncology and autoimmune research and development programs from 2seventy bio, Inc. |
| 2024 | Regulatory Approval | In March, the company received approval from the US Food and Drug Administration for Praluent (alirocumab) injection to treat children with genetic form of high cholesterol. |
| 2024 | Regulatory Approval | In February, the company received approval from the US Food and Drug Administration for linvoseltamab to treat multiple myeloma. |
Competitor Comparison
| Key Parameters | Regeneron Pharmaceuticals Inc | Merck & Co Inc | Pfizer Inc | AbbVie Inc | Bayer AG |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | Germany |
| City | Tarrytown | Kenilworth | New York | North Chicago | Leverkusen |
| State/Province | New York | New Jersey | New York | Illinois | Nordrhein-Westfalen |
| No. of Employees | 13,450 | 72,000 | 88,000 | 50,000 | 99,723 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Leonard S. Schleifer, M.D., Ph.D. | President; Chief Executive Officer; Co Chairman | Executive Board | 2023 | 71 |
| George D. Yancopoulos, M.D., Ph.D. | Co Chairman; Chief Scientific Officer; President - Regeneron Laboratories | Executive Board | 2023 | 64 |
| Christopher Fenimore | Senior Vice President - Finance; Chief Financial Officer | Senior Management | 2024 | 52 |
| Bob McCowan | Chief Information Officer; Senior Vice President - IT | Senior Management | 2018 | - |
| Melissa Lozner | Chief Compliance Officer; Senior Vice President | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward